1677-P: Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity

Introduction and Objective: Weight loss and glycemic improvement with incretin-based therapies evolve over time and are influenced by both pharmacologic exposure and lifestyle adherence. Repeated once-weekly tirzepatide dosing plus lifestyle management allows the temporal pattern of glycemic and anthropometric change to be defined. This study aimed to assess progressive changes in weight, central adiposity, glycemic parameters, and reduction in medication with tirzepatide plus lifestyle support. Methods: This retrospective real-world study included 170 adults with T2D receiving once-weekly tirzepatide plus personalized, structured dietary and physical activity interventions. Outcomes were assessed for 12-, 8-, and 4-weekly tirzepatide exposure groups (Months 3, 2, and 1; n=21, 35, and 114, respectively), with changes in body mass index (BMI), body weight, waist circumference (WC), fasting blood sugar (FBS), postprandial blood sugar (PPBS), and medication intensity assessed at each exposure timepoint. Results: Administration of tirzepatide with lifestyle support showed progressive metabolic improvements with BMI (kg/m2), weight (kg), WC (cm), FBS (mg/dL), and PPBS (mg/dL) decreasing by 1.16±0.90, 3.73±2.44, 2.19±0.27, 22.34±24.69, and 52.63±48.02 after 12 weekly doses; 1.36±1.81, 4.29±4.96, 4.25±3.03, 28.28±39.08, and 29.52±27.88 after 8 weekly doses; 1.17±1.73, 3.09±3.25, 3.05±1.67, 16.11±32.96, and 21.89±34.40 after 4 weekly doses, respectively (all p<0.05). The medications also declined across 12-, 8-, and 4-dose exposure groups, with intensity of pharmacotherapy improving as medication burden decreased by 32.08%, 53.97%, and 41.87%, respectively (all p<0.05). Conclusion: Once-weekly tirzepatide, when paired with personalized lifestyle modification, delivered clinically meaningful improvements in adiposity, glycemic control, and reduced diabetes medication needs in routine Indian practice, reinforcing the value of integrated metabolic therapy. Disclosure C.G. Mehra: None. A.M. Raymond: None. A. Sequeira: None. J. Joseline: None. S. Kumar: None.